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Cancer cells accumulate genetic and epigenetic changes that alter gene expression to drive
tumorigenesis. Epigenetic silencing of tumor suppressor, cell cycle, differentiation and DNA repair
genes contributes to neoplastic transformation.
The ING (inhibitor of growth) proteins (ING1–ING5) have emerged as a versatile family of growth
regulators, phospholipid effectors, histone mark sensors and core components of HDAC1/2 – and
several HAT chromatin-modifying complexes. This review will describe the characteristic pathways
by which ING family proteins differentially affect the Hallmarks of Cancer and highlight the various
epigenetic mechanisms by which they regulate gene expression. Finally, we will discuss their
potentials as biomarkers and therapeutic targets in epigenetic treatment strategies.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Out of balance: epigenetics in cancer British developmental biologist. He linked the two ﬁelds ofCancer has been described in terms of ten speciﬁc ‘‘hallmarks’’
that are acquired in different combinations by cells undergoing
the multistep process of carcinogenesis [1]. These include
mutations in tumor suppressor genes and oncogenes, which have
stood the test of time as integral culprits of neoplastic transforma-
tion. Oncogenesis may also be understood as a cascade of clonal
expansions triggered by random attainment of an enabling mutant
genotype [2,3]. Continuously increasing evidence indicates that
epigenetic alterations also participate with genetic abnormalities,
contributing to the hallmarks that drive the process of
tumorigenesis [2,4].
The term ‘‘epigenetics’’ was originally coined in the middle of
the twentieth century by Conrad Waddington (1905–1975), aepigenesis and genetics to describe ‘‘the causal interactions
between genes and their products, which bring the phenotype into
being’’ [5–7]. Despite decades of debate, the deﬁnitions of
‘‘epigenetics’’ or ‘‘epigenetic’’ remain somewhat controversial [8].
Most commonly, the term is used to describe reversible,
chromatin-based events that regulate DNA-templated processes
without altering DNA primary sequence [9]. This deﬁnition will
be used in this article.
The myriad characteristics of a cellular phenotype that are not
due to primary DNA sequence alterations evolve by stable
maintenance during differentiation, allowing cells to have distin-
guishable identities while harboring identical genetic information.
This means that gene expression patterns are unique, heritable and
mediated by chromatin modiﬁcations. One major level of chroma-
tin regulation is at the level of the nucleosome, a simple repeating
unit of chromatin that contains about 146 bp of DNA wrapped
around an octamer of basic histone proteins. Nucleosomal proteins
are subject to modiﬁcation by phosphorylation, ubiquitination,
SUMOylation, methylation, citrullination and acetylation, most of
which affect histone turnover and/or nucleosome stability. Along
with DNA methylation, histone modiﬁcation has emerged as a
promising target in cancer treatment. Acetylation induced by
histone acetyltransferases (HAT) is associated with high
transcriptional activity, while histone hypoacetylation induced by
histone deacetylases (HDAC) usually results in gene silencing.
The epigenetic mechanism that is arguably the best understood
currently is the transcriptional repression or activation of a
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methylation of DNA in GC-rich promoter regions (CpG islands) of
these genes [9–14].A physiological epigenetic balance is maintained when some
specialized genes determining the phenotype of differentiated cells
are permanently turned on, while others are permanently turned
off. Loss of this balance can result in a cancer epigenome, where
aberrant transcription of growth regulatory genes and dysregu-
lated signaling pathways enable emergence of the Hallmarks of
Cancer.
In fact, epigenetic imbalance is suspected to be the key
initiating mechanism in some forms of cancer [15]. For example,
the identiﬁcation of genes that are speciﬁcally hypermethylated
(silenced), or hypomethylated (transcriptionally activated),
spawned new concepts of cancer initiation, progression and
therapy [2,9]. Similar to gene mutations that occur frequently
in speciﬁc cancers, various high-frequency epigenetic mutations
have already been discovered in speciﬁc genes. To name a few,
the tumor suppressor and growth-regulatory genes Von
Hippel–Lindau (VHL) in Wilms Tumor, CDKN2A (encoding the
tumor suppressors INK4A and ARF), MGMT (encoding the DNA
repair enzyme 0(6)-methylguanine-DNA-methyltransferase), Rb
as well as the ‘‘large tumor suppressor gene 1’’ (LATS1) are
hypermethylated in their promoter regions [16–18]. Another
mechanism involved in transcriptional and posttranscriptional
gene silencing is speciﬁc base pairing between microRNAs
(miRNAs) and their growth-regulatory targets. miRNAs are vital
for normal development and are frequently compromised in
diseases such as cancer [19]. Finally, aberrant epigenetic status
in cancers is also deﬁned by posttranslational local and global
chromatin modiﬁcations [2]. Therefore, studying epigenetics in
cancer should not only focus on the discovery of growth-
regulatory genes affected, but also on the recognition of the
corresponding culprits: chromatin modifying non-histone
proteins, that are dysregulated in cancer cells, such as the ING
family of proteins that is the major subject of this review.In addition to screening cancer-cell genomes and epigenomes
for genetic and epigenetic alterations of tumor suppressor genes,
cancer patients may proﬁt from the identiﬁcation and analysis
of chromatin-regulatory proteins, since they represent potential
biomarkers and targets for epigenetic-based cancer therapies.2. Almost two decades of learnING: from candidate tumor
suppressors to a PHD in epigenetics
The ING (INhibitor of Growth) family of genes and proteins
(ING1–ING5) was originally identiﬁed in 1996, using subtractive
hybridization between cDNAs from a normal mammary epithelial
cell strain and several transformed breast cancer cell-lines, fol-
lowed by an in vivo functional screen for tumourigenesis [20]. INGs
are evolutionarily well-conserved proteins that localize primarily
in the nucleus [21]. Abnormal nuclear morphology is a frequently
noted change in cancer cells ever since, more than a century ago,
Theodor Boveri described the ﬁrst genetic alteration in cancer:
abnormal chromatin [22,23]. The INGs are multidomain
proteins that share motifs targeting them to the nucleus and to
different chromatin domains, thereby enabling them to exert their
growth-regulatory functions.2.1. All PHDs: on the histone mark, (de)acetylate, go!
All ING proteins share a highly conserved plant homeodomain
(PHD) ﬁnger (Fig. 1) [21,24,25]. The PHD selectively binds to the lysine
4 residue of histone H3with afﬁnity increasingwithmethylation state
such that H3K4me3 > H3K4me2 > H3K4me. The H3K4me3 mark is
preferentially located at promoters and downstream of
transcription start sites [26–34]. It is bound by all ING-PHDs with
strong but biologically relevant dissociation constants (Kds of
<10 lM), and competes for binding with a small number of other
PHD-containing proteins. Interaction of INGs with H3K4me3,
partially by recruitment of the growth arrest DNA damage protein
45a (Gadd 45a), directs the acetylation and methylation status of
histone tails, thereby stimulating or silencing growth-inhibitory
or pro-proliferative target gene promoters, in multiple species
[29,35–39]. Since all of the ING proteins are stoichiometric
members of HAT (ING3–ING5) or HDAC (ING1, ING2) complexes,
once they bind the H3K4me3 mark through their PHD, they can
direct HAT or HDAC activity to the immediate vicinity of the mark
to affect chromatin structure.Through their conserved PHD, all ING family proteins act as
H3K4 methylation-sensitive sensors, thereby transcriptionally
regulating target genes. Therefore, they are considered as
‘‘readers’’ of the epigenetic code.2.2. Nuclear architects sharING motifs
As shown in Fig. 1, ING proteins all encode one or more nuclear
localization signals (NLS) that are needed for efﬁcient nuclear tar-
geting [40]. Several of the ING proteins also contain short, highly
basic nucleolar translocation sequences (NTS) within the NLS, which
translocate them to the nucleoli in response to DNA damage.
Mutation of the NTS results in the loss of stress-induced nucleolar
targeting and subsequently reduced levels of apoptosis [41].
Many studies to date reporting on the impact of nuclear struc-
ture on gene regulation have been performed using developmental
systems or aging models such as the Hutchinson–Gilford Progeria
syndrome (HGPS), that has a clear link to disruption of nuclear
morphology and gene expression by mutation of the gene encoding
lamin A. HGPS is a rare developmental autosomal dominant
condition characterized by accelerated aging that begins in early
childhood and leads to death at a mean age of 13 years [42].
ING1 is one of the genes that is transcriptionally repressed in HGPS
and all ING proteins contain a sequence, the lamin interaction
domain (LID), that is unique in the entire human proteome. The
LID interacts speciﬁcally with lamin A and seven other proteins,
with lamin A being the highest scoring hit [43]. The interaction
between the LID and lamin A is believed to help tether ING(1) in
the nucleus, thereby localizing its functions as an epigenetic
modiﬁer. Considering that HGPS cells feature aberrant chromatin
structure and that ING1 does not interact with the mutant form
of lamin A called progerin [43], this raises the possibility that
ING proteins contribute to transduction of the HGPS phenotype
through altering the epigenetic status of lamin A mutant cells.
Like aging, cancer is associated with global misregulation of
gene expression [44–46], suggesting that both aging and cancer
are in some aspects, developmental diseases. For example, loss of
lamin A due to promoter methylation of the lamin A/C gene has
been reported for hematologic malignancies [47,48]. While normal
B and T cells express lamin A and ING(1), leukemia and lymphoma
cells do not, nor do some normal progenitor cells or early B/T cell
intermediaries [46,49]. ING2 is overexpressed in colon cancer
[50], whereas loss of lamin A is common and a risk factor for
Fig. 1. Nuclear architects with shared and unique domains and motifs: structure of ING family proteins. ING family proteins contain a well conserved plant homeodomain
(PHD) and lamin interaction domains (LID) through which they function as H3K4me3 sensors, and bind to Lamin A, respectively. A nuclear localization sequence (NLS) that
targets them to the nucleus via karyopherin binding also contains basic nucleolar targeting sequences (NTS, black boxes) but these have only been demonstrated to be active
in ING1 and so are indicated in gray in other ING members. The NLS region has also been reported to bind p53. The polybasic region (PBR) binds both bioactive phospholipids
(PIs) and ubiquitin (Ub) while ARF and SAP30 have been shown to interact with the amino-terminal half of ING1. Proliferating cell nuclear antigen (PCNA) binds speciﬁcally to
ING1b via the PCNA-interacting protein (PIP) motif, regulating apoptosis and DNA repair in response to DNA damage. The functions of the partial bromodomain (PBD) still
have to be characterized. Two phosphorylation sites located on serines 126 and 199 (S126, S199) have been reported to regulate the half-life of ING1 and alter subcellular
localization, respectively. PHD details (rectangular box): Amino acid sequences of ING PHD zinc ﬁngers that speciﬁcally bind H3K4me3 contain Cys and His residues spaced to
coordinate two zinc ions (purple rectangles). The enabling Cys and His residues form an aromatic cage (gray rectangles), while other residues contribute speciﬁc hydrogen
bonds required for recognizing the H3K4me3 histone mark.
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tors localized by lamin A, colon cancer cells may upregulate ING2
to compensate for lamin A deﬁciency.Aging and cancer share many common features of a perturbed
nuclear architecture and aberrant gene expression that may be
partially due to dysregulated interactions between lamin A and
ING proteins.2.3. Unique motifs for linlNG tumor suppression to transcriptional and
post-translational regulation
ING1 also contains a partial bromodomain (PBD) [21] (Fig. 1).
This motif can interact with SAP30 of the Sin3-HDAC1 and HDAC2
complexes [52], thereby regulating transcription [32,53]. Further-
more, a polybasic region (PBR) adjacent to the PHD, is unique for
ING1 and ING2 (Fig. 1). Within the human proteome, the ING2
protein shows the strongest afﬁnity for bioactive phosphoinosi-
tides such as phosphatidylinositol 5-phosphate (PtdIns(5)P) in
the nucleus. This interaction regulates the growth inhibitory
effects of ING2 in a p53-sensitive manner [54,55] and is of
biological signiﬁcance for the following reasons: phospholipids
that speciﬁcally bind to ING1 and ING2 are stress-inducible and
highly bioactive. This may explain why ING1 and ING2 proteins
targeting HDAC complexes to chromatin are strongly induced in
response to stress. Additionally, the PBR overlaps with a
ubiquitin-interaction motif (UIM) in the C-terminal region of the
INGlb isoform [56] (Fig. 1). Ubiquitin and phosphorylated lipid
species compete for binding to this site, thereby linking bioactive
lipid signaling to ubiquitin-mediated proteasomal degradation
[56]. The PBR/UIM of INGlb also interacts with mono-ubiquitinated
p53. As a result, the p53 tumor suppressor is stabilized, most likely
by blocking polyubiquitination, through targeting deubiquitination
by the herpesvirus-associated ubiquitin-speciﬁc protease HAUSP
[56].
With the exception of ING1, all ING proteins also have a leucine
zipper-like region (LZL) [21] (Fig. 1) that can help regulate
nucleotide-excision-repair-associated functions of ING2, the DNA
damage response and cell differentiation [57]. The LZL of ING2 also
interacts with components of HDAC1 complexes and it is a critical
domain in inﬂuencing muscle differentiation by ING2 [57].
The proliferating-cell nuclear antigen (PCNA)-interacting protein
(PIP) is a domain that is unique to ING1b (Fig. 1). ING1b interacts
with PCNA in a UV-inducible manner to initiate DNA repair
and/or apoptosis as a stress response [58]. ING1b also contributes
to E3 ubiquitin ligase Radl8-mediated PCNA mono-ubiquitination.
Mono-ubiquitinated PCNA associates with DNA polymerase g
(Polg) to promote proper lesion bypass and error-free DNA
replication [59].
Last but not least, recently published results indicate that
another domain unique for ING1 and ING2 exists: a SUMOylation-
motif (PDSM), which provides interaction of ING proteins with
the E3-type small ubiquitin-like modiﬁer (SUMO) ligase PIAS4 that
has implications in the DNA damage response [60].Due to their structural characteristics, ING family proteins are
nuclear proteins with the ability to act as:
 histone mark sensors connecting cellular responses to geno-
toxic stress,
 stoichiometric members of HAT and HDAC complexes,
 growth regulators.2.4. Family meetING
ING family proteins were originally characterized as tumor
suppressors based on observations obtained in the era before the
development of siRNA technology [61]. Over the last decade, their
deﬁnition has broadened due to results from multiple siRNA
studies and in vivo knockout models. These revealed that ING
family proteins differentially control cell growth as epigenetic
regulators in different biological contexts.
2.5. ING1 – ImprovING with age
The founding member of the ING family, ING1, is localized on
chromosome 13q34 [21]. The major ING1-isoforms, ING1a and
ING1b, are widely expressed in normal and cancer cells [62,63].
They differ in their N-termini (Fig. 1) and growth-regulatory
effects, with ING1a affecting cell senescence [64,65] and ING1b
contributing to apoptosis [54,58,66–69]. Over almost two decades
of study, ING1 was initially identiﬁed as a type-II tumor suppres-
sor, then also as an inducer of replicative senescence and more
recently as a transcriptional regulator.
2.5.1. ING1 in human cancers
ING1 gene and/or protein expression is down-regulated in
multiple malignancies. These include childhood acute lymphoblas-
tic leukemia [49], neuroblastoma [70], melanoma [71–74], lung
[75–78], ovarian cancer [75,78], malignant glioma [79,80], gastric
[81], colorectal [82], head and neck squamous cell carcinoma
(HNSCC) [83,84], pancreatic [75,85], prostate [75], and breast
cancer [75,86,87]. ING1 has also been identiﬁed as a breast cancer
antigen by serological analysis of recombinant tumor cDNA
expression libraries [88]. ING1-overexpression correlated with
inhibition of metastasis and reduced tumor-induced mortality of
breast cancer in vivo [89]. It was also associated with poor
prognosis in neuroblastoma [63] and bladder cancer [90].
However, most of these reports do not include information on
ING1’s subcellular localization. Since ING proteins, like p53 [91],
have both nuclear and cytoplasmic functions, localization of ING1
should be conﬁrmed before establishing correlations between
expression levels and clinical data.
2.5.2. Mechanisms of ING1 regulation
Ing1-deﬁcient mice are characterized by reduced body size, as
well as earlier onset and higher incidence of lymphomas
[66,67,92–94]. Moreover, high levels of ING1 were observed in re-
gions of mouse embryos, which are known for increased apoptosis
during embryogenesis [95]. Thus, ING1 downregulation in human
cancers may simply reﬂect a less differentiated phenotype. Alterna-
tively, ING1 loss could itself contribute to the neoplastic process.
ING1-downregulation was not due to mutation, but frequently cor-
related with reduced ING1 protein levels [70–87]. These observa-
tions are indicative of epigenetic mechanisms regulating ING1
transcription. ING1 is very GC-rich in four regions that make it a
prime target for CpG-island methylation [96,97]. Indeed, promoter
methylation has been reported for ING1 in ovarian cancers [75] and
chronic lymphoblastic leukemia [98]. Abnormal methylation pat-
terns in other genes can also result in ING1 downregulation, as it
has been shown for murine adult brain cells [99]. Intriguingly, the
microRNA miR-622 is, like ING1 [81], downregulated and involved
in invasion and metastasis of gastric cancer [100]. Moreover, up-
regulation of miR-622 repressed ING1-transcription in this cancer
type [100]. Post-translationally, various growth-inhibitory effects
of ING1 are regulated by phosphorylation at Ser126 [101,102]. Also,
phospho-serine-mediated 14-3-3 binding and nuclear export
regulate the ability of ING1b to transcriptionally regulate the p21
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apoptosis in response to DNA damage [103]. Moreover, the proto-
oncogene Src, a non-receptor tyrosine kinase with an important
role in growth factor signal transduction, phosphorylates ING1b,
relocalizes it to the cytoplasm, thereby regulating its pro-apoptotic
abilities [104]. Overall, valid interpretation of ING1 downregulation
by cancers requiresmore studies of ING1 promotermethylation sta-
tus, of subcellular ING1 protein localization as well as co-expres-
sion analyses of other growth-regulators, including additional
miRNAs, of which ING1 may be a bonaﬁde target.ING1 is downregulated but not mutated in various human can-
cers. ING1 expression is regulated by epigenetic mechanisms, such
as promoter methylation, miR-622 and by PTMs such as stress-
inducible phosphorylation by Src.
2.5.3. Affecting cancer hallmarks by epigenetic regulation
Overexpression of human ING1 causes cell-cycle arrest in the
G0/G1-phase, whereas suppression leads to loss of cellular growth
control and immortalisation [20]. While ING1b is mainly involved
in regulating apoptosis, cellular stress, hormonal responses as well
as inhibition of tumor angiogenesis [105–107], ING1a inhibits
growth by inducing replicative senescence, partially through
inhibiting endocytosis via the Rb-tumor-suppressor pathway
[64,65]. ING1b can efﬁciently induce apoptosis through interactionFig. 2. Left panel: hallmarks of cancer affected by ING-HDAC- and HAT-complexes.Whit
aberrant proliferative signaling, ‘‘No’’-symbol: dysregulated growth suppression, Y: immu
triangles: invasion & metastasis, pipe: pathological angiogenesis, DNA: genome instabili
red ‘‘stop’’-sign: inhibited by ING activity, question-mark: possibly inhibited by ING(5)
family, HDAC1/2 – histone deacetylase 1/2, ING (1–5) – Inhibitor of growth (1–5), JADE –
multiprotein HDAC-associated corepressor complex, Tip60-MYST – HAT of the MYST fa
suppressor 1, BRPF1/2/3 -PHD proteins bridging MOZ and MORF in MYST-HAT-complexes
detailed information on proteins and signaling pathways associated with the tumor suppressiv
modiﬁcation by ING family proteins. (1) Activation: upon cellular stress, p38MAPK is activ
inhibiting its kinase activity and increasing nuclear PIP levels. PIP subsequently binds to I
formation of ING-HDAC or -HAT complexes. (2) Interpretation: ING proteins speciﬁcal
complexes to speciﬁc chromatin loci and target gene promoters (details in main text).
methylation as well as subsequent activation (gene ‘‘on’’) or silencing (gene ‘‘off’’) of gene
of histone modiﬁcations by ING-HDAC and HAT-complexes, ING proteins are removed a
binding to 14-3-3 proteins leading to cytoplasmatic translocation, whereas dephospho
proteins ka or kb and subsequent re-localization of ING to the nucleus. Abbreviations and
HDAC – histone deacetylase, ING – Inhibitor of growth, K4, K14 – core histone subunits, P
– phosphatidylinositol monophosphate, PTM – post-translational modiﬁcation, RNA-Polwith other tumor suppressors like p53 [68,108,109] and with
members of the intrinsic apoptotic pathway such as BCL-2-associ-
ated X protein (BAX) [69]. Moreover, Ingl inhibits proliferation of
mature B cells in mice [110]. In Ing1 knockout mice, however, loss
of p37Ing1 induces Bax expression and promotes DNA damage-in-
duced apoptosis in a p53-independent manner [110]. Ing1-loss also
increases sensitivity to ionizing radiation and is associated with
earlier onset and higher incidence of lymphomas in mice [110].
This may be due to the involvement of Ing1 in regulating various
DNA repair mechanisms in response to stress [111]. These observa-
tions suggest both tumor suppressive and oncogenic effects of
ING1, possibly depending on the species and biological context.e sh
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II –Major Hallmarks of Cancer affected by ING1 (Fig. 2):
 dysregulated growth suppression,
 replicative immortality,
 invasion and metastasis,
 resistance to cell death,
 aberrant proliferative signaling,
 pathological angiogenesis.This potentially dual function of ING1 may be due to its
function as an epigenetic regulator. ING1 can both activate
and repress target genes, since it is an H3K4me3 sensor thatapes and symbols clockwise (according to Hanahan and Weinberg 2011) [1]: arrow:
destruction,1 : replicative immortality, ﬂame: tumor-promoting inﬂammation,
& mutation, cross: resistance to cell death, ‘‘O2’’: deregulated cellular energetics,
ivity. Abbreviations: HAT – histone acetyl transferase, HBO1 – HAT of the MYST
c ﬁnger protein associating with MYST-HATs, mSin3A – core component of large
ly. Subunits/domains not explained in the text: BRMS1 – breast cancer metastasis
PC1/2 -ectopically parting cells 1/2, hEaf6 – subunit of MYST-HAT-complexes. For
unctions of ING proteins: see main text. Right panel: Stress signaling and chromatin
d and then translocated to the nucleus where it phosphorylates PIP4Kb, thereby
1 and ING2. Recognition of the histone mark H3K4me3 by ING proteins results in
bind to H3K4me3 or H3K14me3 recruiting the assigned chromatin remodeling
s results in various distinc histone-PTMs, such as acetylation, deacetylation and
anscription affecting the Hallmarks of Cancer [1]. (3)Migration: after realization
or inactivated by different PTMs [24]. These include phosphorylation-dependent
tion releases ING from 14-3-3, thereby promoting ING binding to karyopherin
bols: ac – acetyl group, me3 – 3-methyl group, HAT – histone acetyl transferase,
phosphatidylinositol, PIP4Kb – phosphatidylinositol-5-P 4-kinase type 2 beta, PIP
RNA polymerase II; yellow pentagons: phosphorylized sites.
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numerous proteins that are important for different epigenetic
modulations, including the Ras, p300 and pl6(INK4a) as well
as DNA methyltransferase 1 associated protein (DMAP1)
[112–116]. Gadd45a requires speciﬁc ING1 binding to
H3K4me3 for DNA demethylation [38], thereby linking histone
methylation to DNA demethylation. Moreover, ING1 is a tran-
scriptional regulator of multiple miRNAs: INGlb overexpression
induces miR-203, miR-375, miR-449b and miR-200c, thereby
downregulating Src and CDK6, to name a few, and promoting
growth inhibition effects [117]. In mouse primary embryonic
ﬁbroblasts, Ing1 regulates the microRNA regulator protein
Dgcr8, a protein involved in the early steps of microRNA
synthesis [118]. These ﬁndings establish a new link between tu-
mor suppression and microRNA biogenesis.ING1 regulates target gene expression by
 recruitment of protein complexes with chromatin-modify-
ing activity to speciﬁc (H3K4me3-marked) promoters,
 regulating Gadd45a-mediated DNA demethylation,
 regulating miRNA expression signatures and biogenesis.2.6. ING2: The Renaissance Protein
ING2 has high amino acid sequence homology to ING1
[21,119,120] (Fig. 1). Two major splicing variants have been
identiﬁed for ING2 (ING2a, ING2b) [121], with the original
‘‘ING2’’ now called ING2a, when required. ING2b lacks the
N-terminus that determines major functions of ING2a [122].
ING2 is characterized by its versatility: it is another histone mark
sensor that can act as a DNA damage responder and phospholipid
signaling effector [123]. In addition to its growth-regulatory
abilities, ING2 possesses essential developmental functions,
particularly in spermatogenesis [93], axon growth, neuronal and
muscle differentiation that are mediated by p53- and
chromatin-mediated mechanisms [124], as well as by
SnoN-induced transcriptional regulation through ING2 [125].
2.6.1. ING2 in human cancers
Expression of ING2 is upregulated in colorectal cancer [50,120],
in Burkitt lymphoma and cervical cancer according to the
Oncomine Database (http://www.oncomine.org/main/login.jsp).
Decreased ING2 expression or loss of heterocygosity have been
found in various types of malignancies as well. These include hepa-
tocellular carcinoma (HCC) [126,127], HNSCC [128] and lung can-
cer [75,129,130]. The subsequent conclusion that ING2 is
generally downregulated in these cancers still needs to be con-
ﬁrmed for the following reasons: most of the associated studies
were carried out using either a relatively small number of cell-lines
[75], or revealed reduced expression of ING2 at the mRNA level, but
no signiﬁcant changes at the protein level [126]. Despite this, and
although subcellular localization of ING2 was cytoplasmatic, even
in normal control tissues, ING2 protein expression correlated with
unfavorable prognosis [126]. However, ING2 is a nuclear protein
[122]. This, as well as additional controls to verify antibody stain-
ing speciﬁcity should be considered before using expression data in
Kaplan–Meier analyses.
2.6.2. Mechanisms of ING2 regulation
Aberrant ING2 levels in cancers appear not to be due to
mutations. Instead, direct binding of the p53 tumor suppressor to
the promoter region of ING2 results in ING2 downregulation
[131]. Considering that about 50% of sporadic cancers arecharacterized by TP53 mutations [132], the upregulation observed
for ING2 in colorectal cancers might be, as outlined above, a feed-
back mechanism due to lamin A loss [51] and/or p53-deﬁciency.
On the other hand, Nutlin 3a, an MDM2 inhibitor that activates
p53, is known to downregulate endogenous ING2 levels through
binding to two p53 binding sites on the ING2 promoter. This
interaction causes senescence in normal cells [131] and could be
a mechanism by which ING2 levels are being reduced in the
remaining other 50% of malignancies with wild-type p53. Hence,
interpretation of ING2 levels in tumors should also include their
p53-status. ING2-upregulation may also be a result of direct bind-
ing of the transcription factor nuclear factor kappa B (NF-jB) to the
ING2 promoter [133]. NF-jB is antiapoptotic and, like ING2, is
overexpressed in colorectal cancer [133]. ING2 protein levels are
also regulated by PTMs, and in particular ubiquitin- and SUMO-
mediated mechanisms. ING2 interacts with ubiquitin ligase Smad
ubiquitination regulatory factor 1 (Smurf1) that targets ING2 for
poly-ubiquitination and proteasomal degradation [134], and is reg-
ulated by SUMOylation, affecting Sin3A activity [135].ING2 is differentially expressed in different cancers, transcrip-
tionally repressed by Nutlin3a-mediated p53-activity and
activated by NF-jB.
ING2 proteins are post-translationally modiﬁed by Smurf-
mediated ubiquitin-dependent proteasomal degradation.2.6.3. Affecting Cancer Hallmarks by epigenetic regulation
ING2 is a damage-inducible gene. The ING2a isoform negatively
regulates cell proliferation through p53 activation via acetylation
mediated by the HAT p300 [136] and by regulating p21 indepen-
dently of p53 [137]. ING2 also mediates transforming growth fac-
tor-b (TGF-b)-dependent responses in epithelial cells. Considering
that TGF-b has growth-inhibitory functions in normal cells and
oncogenic functions in invasivemetastaticmalignancies, the signals
from TGF-bmediated by ING2 appear to differ in normal and cancer
tissue [138,139]. Moreover, ING2a is required for the initial DNA
damage sensing and chromatin regulation in the nucleotide excision
repair process via recruitmentof thedamage-recognitionXeroderma
pigmentosum group A-complementing (XPA) protein to the lesion
site after DNAdamage byUV [140]. In contrast, ING2b alone appears
not to have any growth-regulatory effects [122]. Thus, the two iso-
formsmayhave compensatory roles that protect cells fromcell cycle
arrest and apoptosis, as only loss of both can induce these biological
functions, particularly in p53-deﬁcient cells. These observations im-
ply a role for ING2 proteins in the development of resistance to
conventional cancer treatments, such as DNA damaging agents.
Moreover, differential regulation of the two ING2 isoforms may be
essential for maintenance of irreversible cellular senescence seen
following the induction of high levels of DNA damage.Major Hallmarks of Cancer affected by ING2 (Fig. 2):
 dysregulated growth suppression,
 replicative immortality,
 invasion and metastasis,
 resistance to cell death,
 aberrant proliferative signaling.Loss of Ing2 in Ing2-knockout mice resulted in male sterility and
increased incidence of soft tissue sarcomas [124]. In contrast, ING2
loss in human gastric cancer cells induced G0/G1 arrest and
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ilar to ING1, differential effects in mice and men, in normal and in
cancer cells – a role that is consistent with an epigenetic regulator.
Moreover, the PHD ﬁnger of ING2 integrates phosphoinositide and
chromatin signaling networks to prevent unchecked cell growth:
Upon DNA damage, ING2 binds to H3K4me3 [142,143] mediated
by nuclear PtdIns(5)Ps, thereby recruiting mSin3a/HDAC1 [144]
(Fig. 2). Subsequent promoter binding of the ING2-SIN3A-
HDAC1-complex is regulated by SUMOylation of ING2 [135]. To
date, more than 200 gene promoters have been identiﬁed that
are repressed or activated by ING2 in response to genotoxic stress
[146]. For example, ING2 silences the candidate proto-oncogene
CIP2A [KIAA1524] [144], whereas transcription of matrix metallo-
proteinase 13 (MMP13) can be activated or repressed by ING2,
thereby regulating the invasion ability of cancers [133,145]. ING2
also binds to the p21 promoter to control the G1/S checkpoint
[139]. It regulates cell cycle progression by blocking the function
of RBP1: RBP1 allows recruitment of the mSin3A-HDAC complex
by Rb pocket proteins to induce cell cycle arrest through repression
of E2F-dependent transcription and DNA replication origins [146].
RBP1-associated mSin3A-HDACl activity is inhibited by SIRT1,
which is recruited by ING1 and ING2 proteins [147]. In addition
to regulating gene transcription by HDAC- and HAT crosstalk,
ING2 collaborates with the tumor suppressive SWI–SNF–BRG1-
complex. This is similar to ING1 interacting with the corepressor
Alien in chromatin remodeling and both recruit histone
methyltransferase (HMT) activity to methylate histone H3
[53,138,148,149].ING2 regulates target gene expression by
 stress-inducible, phosphoinositide-mediated recognition of
H3K4me3, subsequent recruitment of the mSin3A/HDAC1
complex and binding of target gene promoters,
 chromatin remodeling via association with SWI/SNF/BRG1,
 methylation of histone H3 through HMT recruitment.2.7. ING3 likes MYSTerious HATs
ING3 was identiﬁed through bioinformatic analyses of the hu-
man genome [62,150]. Its amino acid sequence is the most distinc-
tive among the ﬁve ING proteins evolutionarily (Fig. 1) [21]. ING3
modulates cell growth and p53-mediated transcription [150,151].
Although ING3 is ubiquitously expressed in mammalian tissues, it
has been reported that it is more highly expressed in oocytes from
mice, rhesus monkeys, and humans [152]. Moreover, ING3 has the
highest molecular weight in the family due to long unique, and still
uncharacterized regions. These imply unique roles for this family
member, such as linking developmental functions to chromatin
structure, as recently found in germ and blood cells [152–155].
2.7.1. ING3 in human cancer
Various studies of cancer samples and cell lines analyzed for
ING3 mutation and expression have reported that the ING3 gene
was silenced. These include HNSCC [156,157], HCC [158,159] and
ovarian cancer [75].
2.7.2. Mechanisms of ING3 regulation
ING3 is a miR-21 target gene with a role in monocyte differen-
tiation to dendritic cells [155]. Additionally, ING3 represents a
novel transcription target in the serine/threonin kinase RSK2-
cAMP-response element-binding protein (CREB) pathway: RSK2
signaling through CREB downregulates ING3 to protect HNSCC
cells from the apoptotic ‘‘anoikis’’ process, thereby contributingto cancer cell invasion and tumor metastasis [160]. On the protein
level, ING3 is acetylated on several lysine residues that are all lo-
cated in the unique region of the protein [161]. Thus, ING3 might
be distinctively regulated by acetylation. Like ING1 and ING2,
ING3 is also ubiquitinated leading to proteasomal degradation
[102,162].ING3 is downregulated in human cancers and transcriptionally
regulated by miR-21 and RSK2 signaling through CREB.
ING3 is post-translationally modiﬁed by acetylation and
ubiquitination at Lys residues within its unique regions.2.7.3. Affecting Cancer Hallmarks by epigenetic regulation
Numerous reports consider ING3 as another tumor suppressor
in the family, since it promotes apoptosis in human cancer cells
[148,150]. However, these observations mostly originate from
unphysiological overexpression experiments and may require con-
ﬁrmation by knockdown models. In Caenorhabditis elegans, how-
ever, ing-3 downregulation by siRNA resulted in strong
suppression of stress-induced programmed cell death in germline
cells and in the developing embryo [153].Hallmarks of Cancer potentially affected by ING3 (Fig. 2).
 resistance to cell death,
 aberrant proliferative signaling.The epigenetic acitivities of ING3 support its potential role as a
growth inhibitor in humans: In addition to binding to H3K4me3
similarly to the other ING family members [148], ING3 is a member
of the nucleosome acetyltransferase of H4-Tat-interactive protein-
60 (NuA4-Tip60)-MYST-HAT complex that acetylates the N-termi-
nal tails of histones H4 and H2A [142,143,148,163] (Fig. 2). The
MYST proteins are part of large conserved multisubunit HAT com-
plexes that have diverse roles in gene expression, carcinogenesis,
tumor progression, DNA replication and DNA repair [164]. Because
the NuA4-Tip60 complex is a MYST-HAT complex that acetylates
histones H4 and H2A [165], ING3 may bind to trimethylated ly-
sines of these histones as well. Since histone acetylation and
H3K4me3 recognition associate with transcriptional activation,
ING3 may be a transcriptional activator only, unlike ING1 and
ING2, which can be involved in both transcriptional activation
and suppression. Genes regulated by ING3 have yet to be reported.ING3 is a histone mark (H3K4me3) sensor and member of the
NuA4-Tip60-MYST-ING-HAT complex that may activate target
genes by histone H2A and H4 acetylation.2.8. ING4 – that’s not old HAT but a HAT-trick!
ING4 was identiﬁed by computational homology search [62].
Several alternative transcripts of ING4 have been found so far
[166,167] (Fig. 1). One of them (ING4_vs4) was initially designated
an ING4mutation unique for cancer cells until it was recognized as
a splice variant [168]. All ING4 isoforms are ubiquitously expressed
in various tissues [166]. The roles of each variant still have to be
elucidated, however, designing a speciﬁc siRNA against each vari-
ant remains challenging. ING4_v2, ING4_v3, and ING4_v4 have 1,
3, and 9 amino acids deleted in the NLS, which are important for
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NLS on subcellular localization are controversial [166,165,170].
Thus, ING4 isoforms may distribute differentially in different cell
types and different biological contexts, and interact with different
binding partners to transduce different activities of ING4 during
carcinogenesis.
2.8.1. ING4 in human cancers
ING4 is mainly lost or downregulated at the RNA level in human
cancers. These include astrocytic tumors of the central nervous
system [171,172], breast cancer [75,168,173–175], malignancies
of the gastrointestinal tract [176–178], HNSCC [179,180], HCC
[181,182], melanoma [75,183], lung [75], ovarian [75] and prostate
cancer [75]. Like ING1 [80], ING4 downregulation correlates with
higher WHO grades of malignancy in astrocytoma [172], with
unfavorable prognosis of breast cancer patients [89,173,184] and
with angiogenesis in multiple cancer types [106,184–190] and
other diseases [191].
2.8.2. Mechanisms of ING4 regulation
ING4 is downregulated by miR-650 or miR-214, respectively, in
leukemia, HCC, lung, gastric and pancreatic cancer [186,192–194],
thereby possibly contributing to resistance to apoptosis as well as
to certain anticancer agents [195]. ING4 protein stability and
activity are primarily regulated post-translationally by citrullina-
tion on the NLS-motif. ING4 citrullination alters ING4 half-life,
reduces its ability to acetylate p53 and promotes ING4 degradation
[196].ING4 is downregulated in human cancers and transcriptionally
regulated by miR-214 and miR-650. ING4 is post-translationally
modiﬁed by citrullination on the NLS-motif.2.8.3. Affecting Cancer Hallmarks by epigenetic regulation
In concert with its multiple binding partners such as p53, the
HAT p300, HPH-2, which regulates HIF-a stability, the p65 subunit
of NF-jB, and liprin a1 [61,197], ING4 primarily acts as a tumor
suppressor. Exogenous ING4 reduces cell colony formation, de-
creases S-phase in cycling cells [138,168], and induces cell death
in cancer cells by autophagy [197] or p53-mediated apoptosis
[198]. Ing4-null mice, however, are viable, develop normally and
do not form spontaneous tumors [199]. But in vivo models also re-
vealed that Ing4 plays a major role in the inﬂammatory response of
mice to bacterial components through its ability to suppress NF-jB
activation of select cytokine genes in stimulated macrophages
[199]. Collectively, these results suggest a previously unexplored
role also for the human counterpart ING4 in negatively regulating
NF-jB-mediated innate immunity. Taken together, ING4 appears
to particularly target the three cancer hallmarks angiogenesis, im-
mune destruction and tumor promoting inﬂammation [1](Fig. 2).Major Cancer Hallmarks affected by ING4 (Fig. 2):
 immune destruction,
 tumor promoting inﬂammation,
 angiogenesis.In addition, ING4 binds to H3K4me3 [200] to associate with the
MYST-HB01-JADE-hEAF6-HAT-complex [148,201] (Fig. 2). This
latter complex is responsible for most nucleosomal histone H4
acetylation in eukaryotes, and knockdown experiments indicatedthat Ing4-HB01 association is required for cells to progress
properly through the S-phase of the cell cycle [165]. Moreover,
ING4 bridging HBO1 with JADE proteins promotes transcriptional
activation of erythroid developmental target genes [202]. Although
both the ING3 complex and the ING4 complex include MYST-HATs,
these acetylases are different between the complexes: the ING3
complex includes Tip60 and the ING4 complex includes HBO1 as
a catalytic subunit. The ING4-HB01 complex acetylates histone
H4K16, whereas the Tip60-ING3 complex does not acetylate this
histone residue [165]. These ﬁndings indicate that each ING family
protein has a different elaborate role in transcriptional regulation
through generation of different ‘‘histone code’’ signals.ING4 is a histone mark sensor and a member of the
HB01-JADE-hEAF6 MYST-ING HAT-complex, thereby activating
target genes by acetylation of histone H4.2.9. Lift two HATs to ING5!
ING5 was identiﬁed by computational homology search and
shares high amino acid sequence homology with ING4 (Fig. 1)
[62,198] ING5 associates with HAT complexes and, depending on
the biological context, may have tumor suppressive or oncogenic
abilities (Fig. 2).
2.9.1. ING5 in human cancers
A few lung, pancreatic and ovarian cancer cell lines [75], but
also bone marrow samples from a large cohort of patients with
acute myeloid leukemia (AML) revealed ING5 downregulation,
hinting at a potential tumor suppressive effect of ING5 in these
malignancies [203]. In breast cancer, however, only 2/9 cell lines
showed aberrant, i.e. dereased ING5 gene expression [75]. In the
majority of gastric cancer samples, ING5 is downregulated at
the RNA-, and upregulated on the protein level [204], which may
be due to posttranslational dysregulation. ING5 is also downregu-
lated in HNSCC, in which it has been identiﬁed as a tumor suppres-
sor [205,206]. Moreover, cytoplasmic localization of ING5 was
signiﬁcantly increased in these tumors and inversely correlated
with nuclear ING5 levels that predict a well-differentiated status.
Nuclear localization of ING5 positively correlated with p21 and
p300 expression, and with the apoptotic index, suggesting that sub-
cellular mislocalization of ING5maymodulate the transactivation of
target genes, thereby compromising apoptosis and cell cycle arrest.
In contrast to the cases noted above, ING5 gene expression is
upregulated in colon cancer [61], suggesting an oncogenic function
of ING5 in these malignancies. However, these ﬁndings might also
reﬂect that the subcellular localization of ING5, which was not part
of this analysis, is of major relevance for its growth regulatory
effects: a subsequent study [207] revealed no aberrant ING5 gene
expression, but upregulated protein levels in more than 70% of
patients samples and colon cancer cell lines. Moreover, nuclear
ING5 negatively correlated and cytoplasmatic ING5 positively
correlated with aggressive behavior of the tumors. Thus, both
information on expression and subcellular localization of ING5 is
required for assessing its role in the biology of colon, and most
certainly other cancers. Moreover, expression of REIC [208], a
member of the Dickkopf (Dkk) family, might be of relevance when
interpreting ING5 expression in colon cancers; REIC/Dkk-3 acts as a
tumor suppressor in multiple cancer cell lines by inducing
apoptosis through endoplasmic reticulum stress signaling, and
signiﬁcantly negatively correlated with ING5 expression in colon
cancers [208]. However, further analysis is needed before
establishing whether a functional ING5-Dickkopf interaction
exists.
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In pancreatic cancer, ING5 is negatively regulated by miR-196a,
upregulation of which is associated with poor prognosis [209]. In
mesenchymal stem cells (MSC), ING5 mRNA and protein levels
are regulated by miR-193 to control CDK2-mediated MSC
proliferation [210]. ING5 protein activity is further controlled by
methylation [211] and acetylation [161].ING5 is differentially expressed in different cancers and trans-
criptionally regulated by miR-196a. ING5 proteins are post-trans-
lationally modiﬁed by methylation and acetylation.2.9.3. Affecting cancer hallmarks by epigenetic regulation
Being a genuine ING, ING5 controls growth differently in
different biological settings: ING5 induces cell cycle arrest and
apoptosis in normal and cancer cells [148,198,203,206,209]. In
murine mesenchymal ﬁbroblasts, Ing5 requires Inhibitor of cyclin
Al (INCA1) to promote Fas-induced apoptosis [207]. ING5 is also
involved in p53-dependent stress-signaling, partially by physically
interacting with p53, p300/CBP- and MYST-HATs (Fig. 2), such as
HBO1 and Tip60, thereby inducing the activation of p53-
downstream effectors [148,198,212]. ING5 also associates with
minichromosome maintenance (MCM) proteins. These play an
essential role in DNA replication [148]. Moreover, knockdown of
ING5 completely inhibited DNA synthesis, whereas knockdown of
the HAT HBO1 increased cells in S-phase. Thus, the HBOl-JADE-
ING5-HAT-complex may be involved in carcinogenesis by
enhancingDNAreplication. In normal cells, ING5 inhibitionby siRNA
resulted in increased MSC proliferation [210], and was found to be
part of a network of epigenetic modiﬁers that regulate epidermal
stem cell differentiation [213].Major Hallmarks of Cancer affected by ING5 (Fig. 2):
 dysregulated growth suppression,
 resistance to cell death,
 invasion and metastasis,
 aberrant proliferative signaling.Like other ING family proteins, ING5 is a H3K4me3 sensor
[142,143,214], thereby most certainly regulating both, gene
silencing and activation. ING5 is also a component of two different
HAT complexes [151]. Depending on its catalytic acetyltransferase
subunit, i.e. MOZ/MORF or HBO1, it either binds to histone H3 or
H4, respectively [148]. As a subunit in the HBOl-MYST-ING-HAT-
complex that usually contains BRPF1, ING5 can disassemble BRPF1
from unmethylated H3K4, thereby switching HBO1-speciﬁty from
H3 to H4 tails [215]. This suggests a unique role for ING5 as a
regulator of HAT afﬁnity to speciﬁc histone tails.ING5 is a histone mark (H3K4me3) sensor and member of
the HB01-JADE-hEAF6- and MOZ/MORF-MYST-ING-HAT-
complexes, thereby activating target genes by acetylation of
histones H3 and H4.2.10. Target-ING individual cancer epigenomes: possible implications
for the ING family proteins in epigenetic cancer therapy
Current multimodal treatment concepts for cancer patients are
limited due to toxic side effects in normal cells and frequentdevelopment of resistance in cancer cells. Newer strategies target
well-deﬁned molecular markers, such as overexpressed Her-2 in
breast cancer or Brc-abl fusion in leukemia. They are often effec-
tive initially, but fail when subpopulations of resistant cells
evolve. Thus, the new paradigm of anti-cancer drug development
aims at combating multiple Hallmarks of Cancer simultaneously.
In this context, epigenetic-modulating agents harbor a variety of
options, since they can ðaÞ reverse stem-cell like behavior and
chemoresistance and ðbÞsimultaneously affect multiple signaling
pathways that might be dysregulated in a certain cancer type.
Moerover, every patient, thus every individual cancer, has a
unique histone code, modiﬁcation of which is reversible, thereby
opening a wide therapeutic window and leaving the genetic code
unaffected. Hence, epigenetic ‘‘reprogramming’’ of a cancer cell by
either reactivating silenced tumor suppressors or by silencing
oncogenes may sensitize cancer cells to lower doses of
conventional cytotoxic agents or reverse resistance to other tar-
geted approaches. Indeed, anticancer drugs targeting DNA meth-
yltransferases (DNMTs) and HDACs have demonstrated
antitumor activity in the clinic. To date, the best characterized
and FDA-approved epigenetic modulating antineoplastic agents
are DNMT inhibitors (DNMTi) and HDAC inhibitors (HDACi] for
treatment of hematological malignancies. Success in solid tumors
has been more elusive, possibly due to ineffective delivery, dosing
or scheduling [216]. Hence, different strategies for combining a
DNMTi such as 5azaC with other chemotherapeutics like DNA
damaging agents or an HDACi, are currently under investigation.
Moreover, recent reports on the roles of the bromodomain-con-
taining BET family members and methyltransferase EZH2 in driv-
ing cell growth and survival have provided further validation of
epigenetic regulators as critical drivers of the transformed cancer
cell phenotype [217]. Similar to BET proteins, ING proteins are
components of the write-read-erase concept that has been linked
with the transfer of epigenetic information. Therefore, they repre-
sent both potent biomarkers and a plethora of potential novel tar-
gets for future epigenetic cancer therapy. A model for their
possible implications is presented in Fig. 3.
2.10.1. Target-ING the mSin3A-HDAC-complex: implications for ING1
and ING2
Cell death and caspase 3-mediated apoptosis in breast cancer
cell lines signiﬁcantly increased when combining 5azaC and the
HDACi LBH589 with adenoviral delivery of ING1b [82]. This effect
was not signiﬁcantly dependent on p53-status [89]. It was stron-
gest in estrogene receptor (ER)-negative breast cancer cells, possi-
bly because ING1b can activate transcription of ERa [218,219]. In
vivo, ING1 plus 5azaC signiﬁcantly reduced the sizes of subcutane-
ously xenografted tumors in SCID mice without signiﬁcant toxicity
or development of resistance [89]. These observations suggest a
combination of ING1, DNMTi and HDACi as a promising approach
for patients with ER-negative breast cancer. In glioblastoma multi-
forme (GBM), a common and highly malignant brain tumor, down-
regulation of ING1 by siRNA resulted in reduced FADD and caspase-
3 mediated apoptosis by the HDACi trichostatin A (TSA) [220]. Be-
cause neither FADD nor caspase 3 was observed to be a transcrip-
tional target of ING1 [221,222], ING1 function may rather be to
stabilize or activate members of this apoptotic pathway. Given
the fact that major tumor suppressor pathways are already func-
tionally eliminated in most GBM [223], maintaining ING1 levels
in these cells may allow HDACi-induced apoptosis to be of major
therapeutic impact. Considering that ING1 expression is signiﬁ-
cantly reduced in malignant gliomas [79,80], and that downregula-
tion of ING1 by siRNA also sensitizes p53-deﬁcient malignant
glioma cells to cisplatin-induced cell death [224], ING1 levels in
GBM cells might inﬂuence the choice of chemotherapy. This strat-
egy may also apply to patients with osteosarcoma, since ING1b
Fig. 3. Balanc-ING the cancer epigenome: ING family proteins as potent therapeutic targets for targeting the Hallmarks of Cancer. Abbreviations and symbols: DNMTi – DNA
methyltransferase inhibitor, HDACi – histone deacetylase inhibitor, ING (l–5) – inhibitor of growth (1–5), miR – microRNA, RSK2/CREB -serine/threonin kinase RSK2-
cycloAMP-response element-binding protein pathway, SAHA - suberoylanilide hydroxamid acid. For details: see main text.
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inhibitors to induce p53-mediated cell death in osteosarcoma cells
[225,226]. Considering that ING1 is downregulated in a variety of
common human cancers, including breast cancer and GBM, and
that it is a target of miR-622 in gastric cancer, studying the effects
of modulating microRNA signatures that may regulate ING1 in
other malignancies may represent another step towards individu-
alized cancer therapy.
ING2 is the major molecular target of the HDACi suberoylanilide
hydroxamic acid (SAHA) [227], suggesting that targeting of the
INGs themselves may prove useful in combination with HDACi
and other therapeutic agents that have been shown to induce
ING2, thereby promoting p53-acetylation and subsequent apopto-
sis in cancer cells. This approach may also be effective in cancers
upregulating ING2, such as gastrointestinal cancers. Intriguingly,
ING2 knockdown by siRNA enhanced growth suppression in adeno-
carcinoma cells most efﬁciently when combined with the widely
used cytostatic adriamycin, whereas either single agent alone
was signiﬁcantly less effective [122]. As mentioned earlier, ING2
knockdown suppresses MMP13, thus inhibiting tumor invasion
[133,141]. Moreover, ING2 knockdown sensitizes gastric cancer
cells to chemosensitivity with 5-Fluouracil (5-FU) [141]. Therefore,
therapy with siRNA against ING2 may be an approach to patients
with ING2-overexpressing tumors. However, methods of siRNA
delivery to a targeted location still need to be optimized before
going bedside. An interesting projectwould be to test, whether dose
reduction of DNA-damaging agents, but adding SAHA to the drug
regimen will result in similar or even higher efﬁcacy. Also, inhibit-
ing H3K4me3 binding by targeting the PHD, using small molecular
compounds, may be a way to limit the oncogenic effects of ING2.
The H3K4me3 binding region of the PHD forms substantial grooves
[115], thereby representing potential targets for small molecules.
However, this idea needs further reﬁnement also, in particular withregard to speciﬁty towards the ING2, but not other PHD domains.
Since not all ING proteins function as oncogenes, but do share the
PHD, targeting this domain may not be broadly beneﬁcial.
2.10.2. Target-ING the MYST-ING3/4/5-HAT complexes
ING3 is frequently downregulated in cancers, particularly in
HNSCC and HCC. Moreover, ING3 is negatively regulated by miR-
21, a microRNA that is often upregulated in cancers and associated
with tumor progression [118]. Hence, modulating miR-21 may in-
crease ING3-expression and subsequently activate antiproliferative
genes. In addition, RSK2 signaling through CREB downregulates
ING3, thereby shielding HNSCC cells from apoptosis [160]. Thus,
selective serine/threonin kinase inhibitors may increase ING3 tran-
scription and its transcriptionally activating effects.
In addition to various cancer hallmarks affected by all ING
family proteins, ING4 is the one that has been reported to
additionally affect tumor promoting inﬂammation and immune
destruction. Intriguingly, ING4 has recently been suggested as a
prognostic factor in breast cancer based on its ability to negatively
regulate NF-jB target gene expression [184]. It also promoted
apoptosis in lung cancer cells when co-expressed with Interleukin
(IL)-20 [228]. ING4 is silenced in breast, lung and many other
human cancers, where it can promote sensitivity to conventional
DNA damaging agents in vitro [229–232]. Considering that ING4
is a target of miR-650 and miR-214 in some of these tumors, the
possibility of combination therapy with tumor-speciﬁc miRNA
modulators may be a promising approach.
This concept may also apply to cancers downregulating ING5,
which is a target of miR-193. Interestingly, ING5-downregulation
correlated with sensitivity to tamoxifen in ER-positive breast can-
cer cells in a genome-wide functional RNAi screen [233]. Thus,
ING5 might be involved in estrogene signaling in a subset of breast
cancer patients. Moreover, ING5 expression levels might serve as a
2738 G. Tallen, K. Riabowol / FEBS Letters 588 (2014) 2728–2742biomarker to recognize tamoxifen resistant breast cancer pheno-
types. Considering, that the HBO1-JADE-HAT complex depends
on its association with ING5 in order to enhance DNA replication,
blocking ING5 by siRNA might be a future approach for the treat-
ment of cancers overexpressing ING5, such as colorectal cancer.Concluding Remarks
ING family proteins have proven to be potent targets for
epigenetic cancer therapy, particularly in combination with
conventional treatments. Their stoichiometric residence in
HAT and HDAC complexes and links to DNA methylation
make them logical choices for dysregulation of epigenetic
status in cancer cells as a means of increasing the therapeutic
index of many traditional cancer treatments.Conﬂict of interest
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